1
|
Chen CL, Cook MR, Brown ME, Lumbrezer-Johnson S, Hostnik ET, Lapsley JM, Lerche P, Wavreille VA, Menendez MI, Knopp MV, Linn SC, Premanandan C, Selmic LE. Case Report: Use of PET/CT to Guide Treatment in a Cat With Presentation Consistent With Hodgkin's-Like Lymphoma. Front Vet Sci 2021; 8:619264. [PMID: 33996958 PMCID: PMC8116528 DOI: 10.3389/fvets.2021.619264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 02/24/2021] [Indexed: 11/28/2022] Open
Abstract
An 8-year-old male neutered Domestic Long Hair cat was presented for a cervical swelling that was suspected to be an enlarged left retropharyngeal lymph node. In the absence of other lymphadenopathy, this was initially suspected to be Hodgkin's-like lymphoma. A positron emission tomography–computed tomography (PET/CT) scan was performed using 2-deoxy-2-[18F]-fluorodeoxyglucose (18F-FDG) to assess for evidence of disease in other locations to guide treatment. Multifocal increased radiopharmaceutical uptake was identified, indicating disease in multiple organs. High-grade lymphoma was confirmed on tissue biopsy. As such, systemic cytotoxic chemotherapy was recommended instead of lymph node extirpation surgery. The cat received a modified CHOP chemotherapy protocol and attained a temporary partial remission. After 2 months of treatment, the cat stopped responding to chemotherapy and was eventually euthanized due to a relapse of disease and decreased quality of life. This case describes the utility of PET/CT to guide treatment in a cat with a presentation consistent with Hodgkin's-like lymphoma.
Collapse
Affiliation(s)
- Carolyn L Chen
- Veterinary Medical Center, The Ohio State University, Columbus, OH, United States
| | - Matthew R Cook
- Veterinary Medical Center, The Ohio State University, Columbus, OH, United States
| | - Megan E Brown
- Veterinary Medical Center, The Ohio State University, Columbus, OH, United States
| | | | - Eric T Hostnik
- Veterinary Medical Center, The Ohio State University, Columbus, OH, United States
| | - Janis M Lapsley
- Veterinary Medical Center, The Ohio State University, Columbus, OH, United States
| | - Phillip Lerche
- Veterinary Medical Center, The Ohio State University, Columbus, OH, United States
| | | | - Maria I Menendez
- Department of Radiology, The Wright Center of Innovation in Biomedical Imaging, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Michael V Knopp
- Department of Radiology, The Wright Center of Innovation in Biomedical Imaging, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Sarah C Linn
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, United States
| | - Christopher Premanandan
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, United States
| | - Laura E Selmic
- Veterinary Medical Center, The Ohio State University, Columbus, OH, United States
| |
Collapse
|
2
|
Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M, Oppi S, Viviani S, Bolis S, Trentin L, Gini G, Battistini R, Chauvie S, Sorasio R, Pavoni C, Zanotti R, Cimminiello M, Schiavotto C, Viero P, Mulé A, Fallanca F, Ficola U, Tarella C, Guerra L, Rambaldi A. Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. J Clin Oncol 2020; 38:3905-3913. [PMID: 32946355 DOI: 10.1200/jco.20.00935] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To investigate the role of consolidation radiotherapy (cRT) in advanced-stage Hodgkin lymphoma (HL) presenting at baseline with a large nodal mass (LNM) in complete metabolic response after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy. PATIENTS AND METHODS Advanced-stage (IIB-IVB) HL patients, enrolled in the HD 0607 trial (Clinicaltrial.gov identifier NCT00795613), with both a negative PET after two (PET-2) and six (PET-6) ABVD cycles, who presented at baseline with an LNM, defined as a nodal mass with the largest diameter ≥ 5 cm, were prospectively randomly assigned to receive cRT over the LNM or no further treatment (NFT). RESULTS Among 296 randomly assigned patients, the largest diameter of LNM at baseline was 5-7 cm in 101 (34%; subgroup A) and 8-10 cm in 96 (32%; subgroup B), whereas classic bulky (diameter > 10 cm) was detected in 99 (33%; subgroup C). Two hundred eighty patients (88%) showed a postchemotherapy RM. The median dose of cRT was 30.6 Gy (range, 24-36 Gy). After a median follow-up of 5.9 years (range, 0.5-10 years), the 6-year progression-free survival rate of patients who underwent cRT or NFT was, respectively, 91% (95% CI, 84% to 99%) and 95% (95% CI, 89% to 100%; P = .62) in subgroup A; 98% (95% CI, 93% to 100%) and 90% (95% CI, 80% to 100%; P = .24) in subgroup B; 89% (95% CI, 81% to 98%) and 86% (95% CI, 77% to 96%; P = .53) in subgroup C (classic bulky). CONCLUSION cRT could be safely omitted in patients with HL presenting with an LNM and a negative PET-2 and PET-6 scan, irrespective from the LNM size detected at baseline.
Collapse
Affiliation(s)
- Andrea Gallamini
- Research and Clinical Innovation Department, A. Lacassagne Cancer Center, Nice, France
| | - Andrea Rossi
- Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
| | | | - Marco Picardi
- Hematology, Policlinico Federico II Hospital, Naples, Italy
| | | | | | - Sara Oppi
- Department of Hematology, Businco Hospital, Cagliari, Italy
| | - Simonetta Viviani
- Department of Hematology, IRCCS National Institute of Tumors, Milan, Italy
| | | | - Livio Trentin
- Hematology, Medicine, Padua University, Padua, Italy
| | - Guido Gini
- Hematology, Ospedali Riuniti Le Torrette, Ancona, Italy
| | | | - Stephane Chauvie
- Medical Physics Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | | | - Chiara Pavoni
- Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
| | - Roberta Zanotti
- Hematology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
| | | | | | - Piera Viero
- Hematology Ospedale dell'Angelo, Mestre, Venice, Italy
| | | | - Federico Fallanca
- Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Umberto Ficola
- Nuclear Medicine Department, La Maddalena Hospital, Palermo, Italy
| | - Corrado Tarella
- Onco-Hematology European Institute of Oncology, IRCCS, Milan, Italy.,Department of Health Sciences, University of Milan, Milan, Italy
| | - Luca Guerra
- Nuclear Medicine, San Gerardo University Hospital, Monza, Italy
| | - Alessandro Rambaldi
- Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.,Department of Oncology-Hematology, University of Milan, Milan, Italy
| |
Collapse
|